May 30, 2018 – Epigenomics AG announces that the Company’s blood-based colorectal cancer test Epi proColon® is not included in the updated colorectal cancer screening guidelines of the American Cancer Society published today.
The Company will continue to pursue its goal to provide the significant unscreened patient population in the United States access to this innovative, FDA-approved blood-based test for the detection of colorectal cancer.
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: firstname.lastname@example.org
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.